|
US206877A
(en)
*
|
|
1878-08-13 |
|
Improvement in paper-pulp washers |
|
JPS5328173A
(en)
|
1976-08-06 |
1978-03-16 |
Zenyaku Kogyo Kk |
Novel phenylmethanenitro compound and its preparation
|
|
US4138397A
(en)
|
1978-02-27 |
1979-02-06 |
Richardson-Merrell Inc. |
6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
|
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
|
JPS61103861A
(ja)
|
1984-10-27 |
1986-05-22 |
Nitto Kasei Kk |
アリ−ル置換シアン酢酸エステルの製造方法
|
|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
|
US5716981A
(en)
|
1993-07-19 |
1998-02-10 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic compositions and methods of use
|
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
|
US5510379A
(en)
|
1994-12-19 |
1996-04-23 |
Warner-Lambert Company |
Sulfonate ACAT inhibitors
|
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
|
JPH10213820A
(ja)
|
1997-01-31 |
1998-08-11 |
Canon Inc |
液晶素子及び液晶装置
|
|
WO1998047868A1
(en)
|
1997-04-18 |
1998-10-29 |
Smithkline Beecham Plc |
Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
|
|
CA2294259A1
(en)
|
1997-06-21 |
1998-12-30 |
Roche Diagnostics Gmbh |
Barbituric acid derivatives with antimetastatic and antitumor activity
|
|
PT901786E
(pt)
|
1997-08-11 |
2007-08-07 |
Pfizer Prod Inc |
Disperções farmacêuticas sólidas com biodisponibilidade melhorada
|
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
|
AU740745B2
(en)
|
1997-12-11 |
2001-11-15 |
Biochem Pharma Inc. |
Antiviral compounds
|
|
US6426331B1
(en)
|
1998-07-08 |
2002-07-30 |
Tularik Inc. |
Inhibitors of STAT function
|
|
AUPP609198A0
(en)
|
1998-09-22 |
1998-10-15 |
Curtin University Of Technology |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
|
ES2359235T3
(es)
|
1999-02-24 |
2011-05-19 |
F. Hoffmann-La Roche Ag |
Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1.
|
|
AU6985300A
(en)
|
1999-09-10 |
2001-04-17 |
Novo Nordisk A/S |
Modulators of protein tyrosine phosphatases (ptpases)
|
|
EP1214324B1
(en)
|
1999-09-10 |
2006-06-14 |
Novo Nordisk A/S |
MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
|
|
AUPQ288499A0
(en)
|
1999-09-16 |
1999-10-07 |
Biota Scientific Management Pty Ltd |
Antiviral agents
|
|
US6514964B1
(en)
|
1999-09-27 |
2003-02-04 |
Amgen Inc. |
Fused cycloheptane and fused azacycloheptane compounds and their methods of use
|
|
IT1315267B1
(it)
|
1999-12-23 |
2003-02-03 |
Novuspharma Spa |
Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
|
|
JP2003520042A
(ja)
|
2000-01-24 |
2003-07-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
|
|
TWI284639B
(en)
|
2000-01-24 |
2007-08-01 |
Shionogi & Co |
A compound having thrombopoietin receptor agonistic effect
|
|
DE10038019A1
(de)
|
2000-08-04 |
2002-02-14 |
Bayer Ag |
Substituierte Triazolopyrid(az)ine
|
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
|
US6562989B2
(en)
|
2000-08-07 |
2003-05-13 |
Yale University |
Catalyst for aromatic C—O, C—N, and C—C bond formation
|
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
|
AR030357A1
(es)
|
2000-08-18 |
2003-08-20 |
Lundbeck & Co As H |
Derivados 4 -, 5 -, 6 - y 7-indol
|
|
CN1308310C
(zh)
|
2000-10-20 |
2007-04-04 |
卫材R&D管理有限公司 |
含氮芳环衍生物
|
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
|
GB0102109D0
(en)
|
2001-01-26 |
2001-03-14 |
Syngenta Ltd |
Chemical process
|
|
CA2442654A1
(en)
|
2001-04-10 |
2002-10-10 |
Transtech Pharma, Inc. |
Probes, systems, and methods for drug discovery
|
|
CN1300116C
(zh)
|
2001-04-16 |
2007-02-14 |
卫材株式会社 |
1h－吲唑化合物
|
|
EP1404653B1
(en)
|
2001-06-28 |
2008-08-20 |
Pfizer Products Inc. |
Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
|
|
EP1411928A1
(en)
|
2001-07-20 |
2004-04-28 |
Boehringer Ingelheim (Canada) Ltd. |
Viral polymerase inhibitors
|
|
AUPR738301A0
(en)
|
2001-08-30 |
2001-09-20 |
Starpharma Limited |
Chemotherapeutic agents
|
|
ATE387197T1
(de)
|
2001-11-13 |
2008-03-15 |
Merck Frosst Canada Ltd |
Cyanoalkylamino-derivate als protease-hemmer
|
|
US7332612B2
(en)
|
2001-11-14 |
2008-02-19 |
Teva Pharmaceutical Industries Ltd. |
Amorphous and crystalline forms of losartan potassium and process for their preparation
|
|
CN100506807C
(zh)
|
2001-12-21 |
2009-07-01 |
诺沃挪第克公司 |
作为gk活化剂的酰胺衍生物
|
|
US20030158188A1
(en)
|
2002-02-20 |
2003-08-21 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
|
US7074805B2
(en)
|
2002-02-20 |
2006-07-11 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
|
US20040009956A1
(en)
|
2002-04-29 |
2004-01-15 |
Dehua Pei |
Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic
|
|
AU2003243921B2
(en)
|
2002-06-27 |
2009-05-07 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
|
US20060004010A1
(en)
|
2002-07-10 |
2006-01-05 |
Hiromu Habashita |
Ccr4 antagonist and medical use thereof
|
|
TWI244393B
(en)
|
2002-08-06 |
2005-12-01 |
Idenix Pharmaceuticals Inc |
Crystalline and amorphous forms of beta-L-2'-deoxythymidine
|
|
US20060083784A1
(en)
|
2002-08-07 |
2006-04-20 |
Smithkline Beecham Corporation |
Amorphous pharmaceutical compositions
|
|
AU2003272879A1
(en)
|
2002-09-18 |
2004-04-08 |
Ono Pharmaceutical Co., Ltd. |
Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
|
|
AU2003277162C1
(en)
|
2002-09-30 |
2009-12-24 |
The Regents Of The University Of California |
Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
|
|
JP2004131393A
(ja)
|
2002-10-08 |
2004-04-30 |
Kowa Co |
易溶出性製剤
|
|
WO2004035571A1
(en)
|
2002-10-15 |
2004-04-29 |
Rigel Pharmaceuticals, Inc. |
Substituted indoles and their use as hcv inhibitors
|
|
FR2846327B1
(fr)
|
2002-10-25 |
2006-03-24 |
Merck Sante Sas |
Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
|
|
AU2003286757B2
(en)
|
2002-11-01 |
2009-06-04 |
Merck Sharp & Dohme Corp. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
CA2504153C
(en)
|
2002-11-02 |
2012-07-03 |
Aventis Pharma Deutschland Gmbh |
Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
|
|
DE10251019A1
(de)
|
2002-11-02 |
2004-05-19 |
Aventis Pharma Deutschland Gmbh |
Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
|
|
US20040146941A1
(en)
|
2002-11-04 |
2004-07-29 |
Biliang Zhang |
Chemical encoding technology for combinatorial synthesis
|
|
WO2004056744A1
(en)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
|
|
DE10300017A1
(de)
|
2003-01-03 |
2004-07-15 |
Aventis Pharma Deutschland Gmbh |
Selektive MMP 13 Inhibitoren
|
|
ES2387803T3
(es)
|
2003-01-08 |
2012-10-02 |
Novartis Vaccines And Diagnostics, Inc. |
Agentes antibacterianos
|
|
US6933311B2
(en)
|
2003-02-11 |
2005-08-23 |
Abbott Laboratories |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
|
ES2337254T3
(es)
|
2003-02-14 |
2010-04-22 |
Glaxo Group Limited |
Derivados de carboxamida.
|
|
DE10306941A1
(de)
|
2003-02-18 |
2004-08-26 |
Merck Patent Gmbh |
Benzofuranoxyethylamine
|
|
EP1601657A1
(en)
|
2003-03-12 |
2005-12-07 |
Vertex Pharmaceuticals Incorporated |
Pyrazole modulators of atp-binding cassette transporters
|
|
US20050164951A1
(en)
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
|
WO2004087646A2
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
|
|
DE10315377A1
(de)
|
2003-04-03 |
2004-10-14 |
Merck Patent Gmbh |
Carbonylverbindungen
|
|
PT3345895T
(pt)
|
2003-04-11 |
2020-01-29 |
Ptc Therapeutics Inc |
Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças
|
|
EP1615698B1
(en)
|
2003-04-11 |
2010-09-29 |
High Point Pharmaceuticals, LLC |
New amide derivatives and pharmaceutical use thereof
|
|
WO2004110352A2
(en)
|
2003-05-16 |
2004-12-23 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
|
|
WO2004111014A1
(en)
|
2003-06-06 |
2004-12-23 |
Vertex Pharmaceuticals Incorporated |
Pyrimidine derivatives as modulators of atp-binding cassette transporters
|
|
EP1638505B1
(en)
|
2003-06-27 |
2012-04-25 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Amphiphilic pyridinium compounds, method of making and use thereof
|
|
US20050113576A1
(en)
|
2003-08-05 |
2005-05-26 |
Chih-Hung Lee |
Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
|
|
NZ544935A
(en)
|
2003-08-15 |
2009-08-28 |
Lundbeck & Co As H |
Cyclopropyl derivatives as NK3 receptor antagonists
|
|
KR20060088537A
(ko)
|
2003-09-06 |
2006-08-04 |
버텍스 파마슈티칼스 인코포레이티드 |
Ａｔｐ-결합 카세트 수송체의 조절자
|
|
US20050070718A1
(en)
|
2003-09-30 |
2005-03-31 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
|
EP1680411A2
(en)
|
2003-10-08 |
2006-07-19 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
|
|
TW200522964A
(en)
|
2003-10-16 |
2005-07-16 |
Sankyo Co |
5-aryl-pyrimidine derivatives
|
|
EP1679309A4
(en)
|
2003-10-24 |
2007-03-28 |
Ono Pharmaceutical Co |
ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
|
|
WO2005049018A1
(en)
|
2003-11-14 |
2005-06-02 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
|
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
AU2005210474B2
(en)
|
2004-01-30 |
2011-07-07 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding cassette transporters
|
|
EP1718664A4
(en)
|
2004-02-02 |
2008-08-13 |
Ambrx Inc |
MODIFIED HUMAN FOUR FIXED PROPELLANT (4HB) BEAM POLYPEPTIDES, AND USE THEREOF
|
|
CN1960966A
(zh)
|
2004-03-30 |
2007-05-09 |
加利福尼亚大学董事会 |
含酰肼cftr抑制剂化合物及其用途
|
|
US20050222271A1
(en)
|
2004-03-31 |
2005-10-06 |
Le Huang |
Novel amorphous form of memantine hydrochloride
|
|
FR2868417B1
(fr)
|
2004-04-02 |
2006-06-23 |
Rhodia Chimie Sa |
Procede de formation d'une liaison carbone-carbone
|
|
AU2005249154B2
(en)
|
2004-06-01 |
2011-02-10 |
Luminex Molecular Diagnostics, Inc. |
Method of detecting cystic fibrosis associated mutations
|
|
CA2569402A1
(en)
|
2004-06-04 |
2005-12-22 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
PL2489659T3
(pl)
|
2004-06-24 |
2018-06-29 |
Vertex Pharma |
Modulatory transporterów posiadających kasetę wiążącą atp
|
|
EP1771158A4
(en)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
TABLET FOR PULSE DISTRIBUTION
|
|
GB0416730D0
(en)
|
2004-07-27 |
2004-09-01 |
Novartis Ag |
Organic compounds
|
|
EP1773797A2
(en)
|
2004-08-06 |
2007-04-18 |
Otsuka Pharmaceutical Co., Ltd. |
Aromatic compounds
|
|
DE102004047254A1
(de)
|
2004-09-29 |
2006-04-13 |
Merck Patent Gmbh |
Carbonylverbindungen
|
|
CA2583177A1
(en)
|
2004-10-13 |
2006-04-27 |
Ptc Therapeutics, Inc. |
Compounds for nonsense suppression, and methods for their use
|
|
US7662910B2
(en)
|
2004-10-20 |
2010-02-16 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
|
JPWO2006057448A1
(ja)
|
2004-11-26 |
2008-06-05 |
武田薬品工業株式会社 |
アリールアルカン酸誘導体
|
|
EP1676834A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Sanofi-Aventis Deutschland GmbH |
Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
|
|
JP5024039B2
(ja)
|
2005-02-25 |
2012-09-12 |
小野薬品工業株式会社 |
インドール化合物およびその用途
|
|
EP2363128B1
(en)
|
2005-03-11 |
2016-02-17 |
Vertex Pharmaceuticals Incorporated |
Indole modulators of ATP-binding cassette transporters
|
|
CA2600869A1
(en)
|
2005-03-18 |
2006-09-28 |
The Regents Of The University Of California |
Compounds having activity in correcting mutant-cftr processing and uses thereof
|
|
GB0506133D0
(en)
|
2005-03-24 |
2005-05-04 |
Sterix Ltd |
Compound
|
|
US20100120789A1
(en)
|
2005-03-24 |
2010-05-13 |
Nigel Vicker |
Compound
|
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
|
DK2210884T3
(da)
|
2005-03-28 |
2012-03-26 |
Toyama Chemical Co Ltd |
Fremgangsmåde til fremstilling af 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propionsyre eller salte deraf
|
|
JP2006282534A
(ja)
|
2005-03-31 |
2006-10-19 |
Fuji Photo Film Co Ltd |
アミド類の製造方法
|
|
PL1874306T3
(pl)
|
2005-04-08 |
2012-11-30 |
Ptc Therapeutics Inc |
Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji
|
|
US20070032475A1
(en)
|
2005-04-15 |
2007-02-08 |
Ye Xiaocong M |
Novel compounds useful for bradykinin B1 receptor antagonism
|
|
EP1891018B1
(en)
|
2005-05-24 |
2011-11-16 |
Vertex Pharmaceuticals, Inc. |
Modulators of atp-binding cassette transporters
|
|
JP5143738B2
(ja)
|
2005-08-11 |
2013-02-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
嚢胞性線維症膜コンダクタンス制御因子の調節物質
|
|
ZA200802172B
(en)
|
2005-08-11 |
2009-06-24 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EA015715B1
(ru)
|
2005-08-29 |
2011-10-31 |
САНОФИ-АВЕНТИС Ю. Эс. ЭлЭлСи |
Твердая дисперсия, фармацевтическая композиция, включающая такую дисперсию, способ ее получения и применение для предотвращения и лечения заболеваний, связанных с бензодиазепиновыми рецепторами периферического типа
|
|
EP1933831A2
(en)
|
2005-10-06 |
2008-06-25 |
Vertex Pharmaceuticals, Inc. |
Modulators of atp-binding cassette transporters
|
|
EP1942732A2
(en)
|
2005-11-02 |
2008-07-16 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
|
DK1945632T3
(da)
|
2005-11-08 |
2013-12-16 |
Vertex Pharma |
Heterocycliske modulatorer af ATP-bindende kassettetransportører
|
|
GB0525144D0
(en)
|
2005-12-09 |
2006-01-18 |
Novartis Ag |
Organic compounds
|
|
BRPI0620292B1
(pt)
|
2005-12-21 |
2021-08-24 |
Janssen Pharmaceutica N. V. |
Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
|
|
JP2009521468A
(ja)
|
2005-12-24 |
2009-06-04 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
|
|
AU2006331565A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in CFTR assays and methods therewith
|
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
PL1993360T3
(pl)
|
2005-12-28 |
2017-08-31 |
Vertex Pharmaceuticals Incorporated |
Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
|
|
EP2016065B1
(en)
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
|
|
AR059826A1
(es)
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
WO2007109604A2
(en)
|
2006-03-20 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
|
CA2646335A1
(en)
|
2006-03-20 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
|
JP2009530399A
(ja)
|
2006-03-22 |
2009-08-27 |
シンデクサ ファーマシューティカルズ コーポレーション |
Ｅｒストレスに関連する疾病の治療のための化合物及び方法
|
|
JP5367563B2
(ja)
*
|
2006-03-30 |
2013-12-11 |
ピーティーシー セラピューティクス，インコーポレーテッド |
ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
PL2674428T3
(pl)
|
2006-04-07 |
2017-01-31 |
Vertex Pharmaceuticals Incorporated |
Modulatory transporterów z kasetą wiążącą ATP
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
WO2007134279A2
(en)
|
2006-05-12 |
2007-11-22 |
Vertex Pharmaceuticals Incorporated |
Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
WO2007146712A2
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
WO2008020227A2
(en)
|
2006-08-17 |
2008-02-21 |
Astrazeneca Ab |
Antibacterial pyrrolecarboxamides
|
|
WO2008029168A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
|
WO2008029152A2
(en)
|
2006-09-08 |
2008-03-13 |
Summit Corporation Plc |
Treatment of duchenne muscular dystrophy
|
|
JP2010507577A
(ja)
|
2006-10-23 |
2010-03-11 |
エスジーエックス ファーマシューティカルズ、インコーポレイテッド |
トリアゾロピリダジンタンパク質キナーゼモジュレーター
|
|
CN101715450B
(zh)
|
2006-11-03 |
2013-03-13 |
沃泰克斯药物股份有限公司 |
作为cftr调控剂的氮杂吲哚衍生物
|
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
|
WO2008064259A2
(en)
|
2006-11-21 |
2008-05-29 |
Biokey, Inc. |
Solid dispersion composition comprising fluvastatin
|
|
WO2008065732A1
(fr)
|
2006-11-27 |
2008-06-05 |
Nippon Polyurethane Industry Co., Ltd. |
Procédé de production d'un mélange à base d'isocyanate modifié contenant une liaison allophanate et une liaison isocyanurate
|
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
|
CA2686838C
(en)
|
2007-05-09 |
2017-03-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cftr
|
|
AU2008256717B2
(en)
|
2007-05-25 |
2013-11-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
AU2008266856A1
(en)
|
2007-06-18 |
2008-12-24 |
University Of Louisville Research Foundation, Inc. |
Family of PFKFB3 inhibitors with anti-neoplastic activities
|
|
US8557823B2
(en)
|
2007-06-18 |
2013-10-15 |
Advanced Cancer Therapeutics, Llc |
Family of PFKFB3 inhibitors with anti-neoplastic activities
|
|
EP2178865B1
(en)
|
2007-07-19 |
2015-08-19 |
Lundbeck, H., A/S |
5-membered heterocyclic amides and related compounds
|
|
WO2009023509A2
(en)
|
2007-08-09 |
2009-02-19 |
Vertex Pharmaceuticals Incorporated |
Therapeutic combinations useful in treating cftr related diseases
|
|
JP5389030B2
(ja)
|
2007-08-24 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
（特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
|
|
ES2445442T3
(es)
|
2007-09-14 |
2014-03-03 |
Vertex Pharmaceuticals Inc. |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
NZ620027A
(en)
|
2007-09-14 |
2015-05-29 |
Vertex Pharma |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
JP2011502133A
(ja)
|
2007-11-02 |
2011-01-20 |
メシルジーン インコーポレイテッド |
ヒストンデアセチラーゼの阻害剤
|
|
DK2578571T3
(en)
|
2007-11-16 |
2015-10-05 |
Vertex Pharma |
Isoquinoline modulators of ATP binding cassette transporters
|
|
PT2409975E
(pt)
|
2007-11-22 |
2015-07-27 |
Zenyaku Kogyo Kk |
Dispersões sólidas compreendendo um corpo amorfo composto por um composto antitumoral heterocíclico
|
|
CN101998854A
(zh)
|
2007-12-07 |
2011-03-30 |
沃泰克斯药物股份有限公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的制剂
|
|
LT3170818T
(lt)
|
2007-12-07 |
2020-05-25 |
Vertex Pharmaceuticals Incorporated |
Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
|
|
DK2639222T3
(en)
|
2007-12-07 |
2016-10-03 |
Vertex Pharma |
Methods for preparing cycloalkylcarboxamido-pyridinbenzoesyrer
|
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
NZ586271A
(en)
|
2007-12-13 |
2012-08-31 |
Vertex Pharma |
Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2009086426A2
(en)
|
2007-12-28 |
2009-07-09 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction
|
|
WO2009108657A2
(en)
|
2008-02-28 |
2009-09-03 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl derivatives as cftr modulators
|
|
AU2009231993B2
(en)
|
2008-03-31 |
2013-10-10 |
Vertex Pharmaceuticals Incorporated |
Pyridyl derivatives as CFTR modulators
|
|
US20110071197A1
(en)
|
2008-04-16 |
2011-03-24 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
|
US20090270452A1
(en)
|
2008-04-18 |
2009-10-29 |
Arete Therapeutics, Inc. |
Use of soluble epoxide hydrolase inhibitors in the treatment of smooth muscle disorders
|
|
KR20100137576A
(ko)
|
2008-04-24 |
2010-12-30 |
브리스톨-마이어스 스큅 컴퍼니 |
알츠하이머병을 포함하는 타우-관련 질병의 치료에서의 에포틸론 ｄ의 용도
|
|
US20110112193A1
(en)
|
2008-05-14 |
2011-05-12 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
|
US9447049B2
(en)
|
2010-03-01 |
2016-09-20 |
University Of Tennessee Research Foundation |
Compounds for treatment of cancer
|
|
SMT201800074T1
(it)
|
2008-08-13 |
2018-05-02 |
Vertex Pharma |
Composizione farmaceutica di n-[2,4-bis(1,1-dimetiletil)-5-idrossifenil]-1,4-diidro-4-ossochinolin-3-carbossammide e sua somministrazione
|
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US8895781B2
(en)
|
2008-09-04 |
2014-11-25 |
Georgetown University |
Transition metal-catalyzed C—H amination using unactivated amines
|
|
TW201011009A
(en)
|
2008-09-15 |
2010-03-16 |
Priaxon Ag |
Novel pyrrolidin-2-ones
|
|
EP2349223A2
(en)
|
2008-09-29 |
2011-08-03 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
CN102227424B
(zh)
|
2008-10-23 |
2013-08-14 |
沃泰克斯药物股份有限公司 |
囊性纤维化跨膜传导调节因子的调节剂
|
|
HRP20130536T1
(en)
|
2008-10-23 |
2013-07-31 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
|
|
US20110257223A1
(en)
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
|
AU2009308232B2
(en)
|
2008-10-23 |
2016-02-04 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
RS53868B1
(sr)
|
2008-11-06 |
2015-08-31 |
Vertex Pharmaceuticals Incorporated |
Modulatori atp-vezujućih kasetnih transportera
|
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
|
AR074231A1
(es)
|
2008-11-27 |
2010-12-29 |
Boehringer Ingelheim Int |
Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos.
|
|
JP2012510523A
(ja)
|
2008-12-03 |
2012-05-10 |
プレシディオ ファーマシューティカルズ インコーポレイテッド |
Ｈｃｖｎｓ５ａの阻害剤
|
|
EP2382197B1
(en)
|
2008-12-30 |
2016-10-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US8946419B2
(en)
|
2009-02-23 |
2015-02-03 |
Mallinckrodt Llc |
(+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
|
|
KR20100101055A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물
|
|
ES2654414T3
(es)
|
2009-03-20 |
2018-02-13 |
Vertex Pharmaceuticals Incorporated |
Proceso de preparación de moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
HRP20181261T1
(hr)
|
2009-03-20 |
2018-12-14 |
Vertex Pharmaceuticals Incorporated |
Modulatori regulatora transmembranske provodljivosti cistične fibroze
|
|
GB0905641D0
(en)
|
2009-04-01 |
2009-05-13 |
Serodus As |
Compounds
|
|
KR20120034613A
(ko)
|
2009-04-16 |
2012-04-12 |
센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) |
키나아제 억제제로서 사용을 위한 이미다조피라진
|
|
WO2011005355A1
(en)
|
2009-05-07 |
2011-01-13 |
Achaogen, Inc. |
Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria
|
|
EP2435407B1
(en)
|
2009-05-29 |
2019-12-25 |
RaQualia Pharma Inc. |
Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
|
|
EP2264012A1
(de)
|
2009-06-03 |
2010-12-22 |
Bayer CropScience AG |
Heteroarylamidine und deren Verwendung als Fungizide
|
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
|
AR078278A1
(es)
|
2009-09-09 |
2011-10-26 |
Vifor Int Ag |
Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
|
|
JP5793496B2
(ja)
|
2009-09-17 |
2015-10-14 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
アザ二環式化合物を調製するプロセス
|
|
US9334230B2
(en)
|
2009-09-18 |
2016-05-10 |
Nanyang Technological University |
Process of forming an amide
|
|
CA2777245A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
CA2778493A1
(en)
|
2009-10-23 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
|
|
AU2010310612A1
(en)
|
2009-10-23 |
2012-06-14 |
Vertex Pharmaceuticals Incorporated |
Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
WO2011109059A1
(en)
|
2010-03-01 |
2011-09-09 |
Gtx, Inc. |
Compounds for treatment of cancer
|
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
US8471029B2
(en)
|
2010-03-19 |
2013-06-25 |
Vertex Pharmaceutical Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
US20110251253A1
(en)
|
2010-03-25 |
2011-10-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
|
|
RS62767B1
(sr)
|
2010-04-07 |
2022-01-31 |
Vertex Pharma |
Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
|
|
MX2012011655A
(es)
|
2010-04-07 |
2012-11-23 |
Vertex Pharma |
Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
|
|
EP3045452A1
(en)
|
2010-04-22 |
2016-07-20 |
Vertex Pharmaceuticals Inc. |
Process of producing cycloalkylcarboxamido-indole compounds
|
|
AU2011242457A1
(en)
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
EP2560649A1
(en)
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
AU2011242454A1
(en)
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
EP2787043B1
(fr)
|
2010-04-30 |
2018-03-21 |
Total Marketing Services |
Utilisation de dérivés organogelateurs dans des compositions bitumineuses pour améliorer leur résistance aux agressions chimiques
|
|
TW201202250A
(en)
|
2010-05-20 |
2012-01-16 |
Vertex Pharma |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
|
CN102917708B
(zh)
|
2010-05-20 |
2015-11-25 |
森普拉制药公司 |
制备大环内酯和酮内酯及其中间体的方法
|
|
EP2575814A1
(en)
|
2010-05-20 |
2013-04-10 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
US20120149708A1
(en)
|
2010-06-17 |
2012-06-14 |
George Mason University |
Modulators of viral transcription, and methods and compositions therewith
|
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
|
UA110113C2
(xx)
|
2010-07-29 |
2015-11-25 |
|
Біциклічні азагетероциклічні карбоксаміди
|
|
EP2608779A2
(en)
*
|
2010-08-23 |
2013-07-03 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
|
|
WO2012027731A2
(en)
|
2010-08-27 |
2012-03-01 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
WO2012049555A1
(en)
|
2010-10-13 |
2012-04-19 |
Lupin Limited |
Spirocyclic compounds as voltage-gated sodium channel modulators
|
|
JP2013540145A
(ja)
|
2010-10-21 |
2013-10-31 |
ウニベルシテート デス ザールランデス |
コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
WO2012079583A1
(en)
|
2010-12-15 |
2012-06-21 |
Aarhus Universitet |
System providing controlled delivery of gaseous co for carbonylation reactions
|
|
CA2827392A1
(en)
|
2011-02-24 |
2012-08-30 |
Emory University |
Noggin blocking compositions for ossification and methods related thereto
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
CN102731492B
(zh)
|
2011-03-30 |
2016-06-29 |
江苏恒瑞医药股份有限公司 |
环己烷类衍生物、其制备方法及其在医药上的应用
|
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
|
WO2013005057A1
(en)
|
2011-07-07 |
2013-01-10 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
New compounds
|
|
EP2753605B1
(en)
|
2011-09-09 |
2019-03-27 |
Lantheus Medical Imaging, Inc. |
Compositions, methods, and systems for the synthesis and use of imaging agents
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
EP2755967B1
(en)
|
2011-09-16 |
2015-10-21 |
Novartis AG |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
EP2755652B1
(en)
|
2011-09-16 |
2021-06-02 |
Novartis AG |
N-substituted heterocyclyl carboxamides
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
GB201116559D0
(en)
|
2011-09-26 |
2011-11-09 |
Univ Leuven Kath |
Novel viral replication inhibitors
|
|
EP2773349A1
(en)
|
2011-11-02 |
2014-09-10 |
Vertex Pharmaceuticals Incorporated |
Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
|
|
US9254291B2
(en)
|
2011-11-08 |
2016-02-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
US20140127901A1
(en)
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
|
WO2013086131A1
(en)
|
2011-12-06 |
2013-06-13 |
The Trustees Of The University Of Pennsylvania |
Inhibitors targeting drug-resistant influenza a
|
|
US8772541B2
(en)
|
2011-12-15 |
2014-07-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
|
|
EP2606726A1
(de)
|
2011-12-21 |
2013-06-26 |
Bayer CropScience AG |
N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide
|
|
LT2806859T
(lt)
|
2012-01-25 |
2019-10-25 |
Vertex Pharma |
3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzenkarboksirūgšties kompozicijos
|
|
BR112014021090B1
(pt)
|
2012-02-27 |
2023-01-24 |
Vertex Pharmaceuticals Incorporated |
Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
|
|
US9217050B2
(en)
|
2012-04-03 |
2015-12-22 |
3M Innovative Properties Company |
Crosslinkable composition comprising photobase generators
|
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
US9528016B2
(en)
|
2012-04-26 |
2016-12-27 |
Xerox Corporation |
Phase change inks comprising crystalline amides
|
|
US9228101B2
(en)
|
2012-04-26 |
2016-01-05 |
Xerox Corporation |
Rapidly crystallizing phase change inks and methods for forming the same
|
|
US8888905B2
(en)
|
2012-04-26 |
2014-11-18 |
Xerox Corporation |
Fast crystallizing crystalline-amorphous ink compositions and methods for making the same
|
|
US20130284054A1
(en)
|
2012-04-26 |
2013-10-31 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
|
CA2813472A1
(en)
|
2012-04-26 |
2013-10-26 |
Xerox Corporation |
Rapid solidifying crystalline-amorphous inks
|
|
EP2861577B1
(en)
|
2012-05-25 |
2017-01-04 |
Boehringer Ingelheim International GmbH |
Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof
|
|
GB2502624A
(en)
|
2012-06-01 |
2013-12-04 |
Univ East Anglia |
Phosphoramide and phosphoramide-based catalysts and their use in intermolecular aziridination
|
|
WO2013185112A1
(en)
*
|
2012-06-08 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Pharmaceuticl compositions for the treatment of cftr -mediated disorders
|
|
JP6294314B2
(ja)
|
2012-06-08 |
2018-03-14 |
マサチューセッツ インスティテュート オブ テクノロジー |
ホスフィン配位パラジウムスルホナートパラダサイクル
|
|
FR2992317B1
(fr)
|
2012-06-22 |
2016-05-13 |
Diverchim |
Procede de preparation de peptides chiraux
|
|
WO2014002106A1
(en)
|
2012-06-25 |
2014-01-03 |
Cadila Healthcare Limited |
Novel compounds for the treatment of dyslipidemia and related diseases
|
|
WO2014011050A1
(en)
|
2012-07-12 |
2014-01-16 |
Proqr Therapeutics B.V. |
Exon replacement with stabilized artificial rnas
|
|
ES2584856T3
(es)
|
2012-07-12 |
2016-09-29 |
Proqr Therapeutics Ii B.V. |
Oligonucleótidos para realizar un cambio en la secuencia de una molécula de arn diana presente en una célula viva
|
|
US9012496B2
(en)
|
2012-07-16 |
2015-04-21 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
|
|
CN104812382A
(zh)
|
2012-09-20 |
2015-07-29 |
坦普尔大学 |
取代的烷基二芳基衍生物、制备方法和用途
|
|
BR102012025405A2
(pt)
|
2012-10-05 |
2014-10-07 |
Fundação Universidade De Brasília |
Processo de obtenção de amidas via aminólise catalítica de ésteres e ácidos carboxílicos em líquidos iônicos
|
|
JPWO2014068893A1
(ja)
|
2012-10-29 |
2016-09-08 |
コニカミノルタ株式会社 |
位相差フィルム、円偏光板、及び画像表示装置
|
|
SMT201800590T1
(it)
|
2012-11-02 |
2019-01-11 |
Vertex Pharma |
Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
|
|
WO2014078479A2
(en)
|
2012-11-14 |
2014-05-22 |
The Board Of Regents Of The University Of Texas System |
INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
|
|
JP6146990B2
(ja)
|
2012-11-16 |
2017-06-14 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたｃｆｔｒ増強物質
|
|
PL2922845T3
(pl)
|
2012-11-20 |
2018-11-30 |
Merial, Inc. |
Związki przeciwrobacze oraz ich kompozycje i sposób stosowania
|
|
ITMI20122065A1
(it)
|
2012-12-03 |
2014-06-04 |
Univ Padova |
Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
|
|
US20150346185A1
(en)
|
2012-12-05 |
2015-12-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Diagnosis of cystic fibrosis
|
|
EP2928532A4
(en)
|
2012-12-07 |
2016-06-29 |
Parion Sciences Inc |
NOSE CANNULA FOR THE ADMINISTRATION OF MEDICAMENTS IN AEROSOL FORM
|
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
|
US20140296164A1
(en)
|
2013-03-29 |
2014-10-02 |
Calista Therapeutics, Inc. |
Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
|
|
US9382254B2
(en)
|
2013-05-07 |
2016-07-05 |
Galapagos Nv |
Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
|
|
US20160194299A1
(en)
|
2013-05-24 |
2016-07-07 |
The California Institute For Biomedical Research |
Compounds for treatment of drug resistant and persistent tuberculosis
|
|
JP2014232188A
(ja)
|
2013-05-29 |
2014-12-11 |
コニカミノルタ株式会社 |
セルロースアシレートフィルム、円偏光板及び画像表示装置
|
|
AU2014302458A1
(en)
|
2013-06-26 |
2015-12-24 |
Proteostasis Therapeutics, Inc. |
Methods of modulating CFTR activity
|
|
HRP20181541T1
(hr)
|
2013-08-08 |
2018-11-16 |
Galapagos Nv |
Tieno[2,3-c]pirani kao cftr modulatori
|
|
US9688990B2
(en)
|
2013-09-12 |
2017-06-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for treatment of cystic fibrosis
|
|
CA2924527C
(en)
|
2013-09-20 |
2022-07-12 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Compounds for treating prostate cancer
|
|
WO2015050984A1
(en)
|
2013-10-01 |
2015-04-09 |
New York University |
Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
|
|
WO2015054337A1
(en)
|
2013-10-09 |
2015-04-16 |
Emory University |
Heterocyclic coupling catalysts and methods related thereto
|
|
CA2930199C
(en)
|
2013-11-12 |
2022-10-25 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
|
|
KR20150062652A
(ko)
|
2013-11-29 |
2015-06-08 |
삼성전자주식회사 |
초음파 감응성 리포좀, 그를 포함한 약제학적 조성물 및 그를 이용하여 개체의 체내에 활성제를 전달하는 방법
|
|
EP3089746A4
(en)
|
2013-12-30 |
2017-08-30 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
WO2015134973A1
(en)
|
2014-03-07 |
2015-09-11 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
|
JP2015172005A
(ja)
|
2014-03-11 |
2015-10-01 |
国立大学法人 東京大学 |
鉄触媒によるカップリング化合物の製造方法
|
|
WO2015138934A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
AU2015229188A1
(en)
|
2014-03-13 |
2016-09-29 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing CFTR activity
|
|
PL3925607T3
(pl)
|
2014-04-15 |
2023-10-30 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
|
|
WO2015172046A1
(en)
|
2014-05-08 |
2015-11-12 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
|
US10864213B2
(en)
|
2014-05-12 |
2020-12-15 |
Verona Pharma Plc |
Treatment
|
|
CN106413673A
(zh)
|
2014-05-16 |
2017-02-15 |
利奎德股份有限公司 |
角蛋白处理制剂和方法
|
|
MX375153B
(es)
|
2014-05-19 |
2025-03-06 |
Boehringer Ingelheim Animal Health Usa Inc |
Compuestos antihelminticos.
|
|
CN106573907B
(zh)
|
2014-06-05 |
2020-09-08 |
默克专利有限公司 |
喹啉衍生物及其用于神经退化性疾病的用途
|
|
EP3157917B1
(en)
|
2014-06-19 |
2020-03-18 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
|
EP3179870B1
(en)
|
2014-08-13 |
2023-10-04 |
Akeso Biomedical Inc. |
Antimicrobial compounds and compositions, and uses thereof
|
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
|
CN115028619A
(zh)
|
2014-09-10 |
2022-09-09 |
Epizyme股份有限公司 |
Smyd抑制剂
|
|
WO2016050209A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种异官能化聚乙二醇衍生物、制备方法及其生物相关物质
|
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
|
WO2016050208A1
(zh)
|
2014-10-01 |
2016-04-07 |
厦门赛诺邦格生物科技有限公司 |
一种多官能化聚乙二醇衍生物修饰的生物相关物质
|
|
US11324827B2
(en)
|
2014-10-01 |
2022-05-10 |
Xiamen Sinopeg Biotech Co., Ltd. |
Multifunctionalized polyethylene glycol derivative and preparation method therefor
|
|
US9855249B2
(en)
|
2014-10-02 |
2018-01-02 |
Flatley Discovery Lab, Llc |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
|
IL313498A
(en)
|
2014-10-06 |
2024-08-01 |
Vertex Pharma |
Modulators of the cystic fibrosis transmembrane conductance regulator
|
|
EP3204007B1
(en)
|
2014-10-06 |
2023-12-20 |
Apm Therapeutics 1, Inc. |
Triazolopyridine compounds and methods for the treatment of cystic fibrosis
|
|
ES2702288T3
(es)
|
2014-10-07 |
2019-02-28 |
Vertex Pharma |
Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
|
|
WO2016057811A1
(en)
|
2014-10-08 |
2016-04-14 |
Nivalis Therapeutics, Inc. |
Methods for the treatment of cystic fibrosis
|
|
US20160108406A1
(en)
|
2014-10-08 |
2016-04-21 |
University Of Iowa Research Foundation |
Method of regulating cftr expression and processing
|
|
GB201418892D0
(en)
|
2014-10-23 |
2014-12-10 |
Proqr Therapeutics B V |
DNA editing
|
|
WO2016066582A1
(en)
|
2014-10-28 |
2016-05-06 |
Bci Pharma |
Nucleoside kinase inhibitors
|
|
CN107427490A
(zh)
|
2014-10-31 |
2017-12-01 |
艾伯维公司 |
取代的四氢吡喃和使用方法
|
|
KR102788925B1
(ko)
|
2014-10-31 |
2025-04-02 |
애브비 에스.에이.알.엘. |
치환된 크로만 및 이의 사용 방법
|
|
SI3221692T1
(sl)
|
2014-11-18 |
2021-11-30 |
Vertex Pharmaceuticals Inc. |
Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
|
|
WO2016086015A1
(en)
|
2014-11-25 |
2016-06-02 |
University Of Rochester |
Myoglobin-based catalysts for carbene transfer reactions
|
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
|
WO2016086136A1
(en)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
CA2971855A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
WO2016105477A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
WO2016105468A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
|
EP3236983B1
(en)
|
2014-12-24 |
2019-04-17 |
Kither Biotech S.r.l. |
Novel pi3k gamma inhibitor peptide for treatment of respiratory system diseases
|
|
US10167278B2
(en)
|
2014-12-31 |
2019-01-01 |
Auspex Pharmaceuticals, Inc. |
Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2016107603A1
(zh)
|
2015-01-01 |
2016-07-07 |
成都贝斯凯瑞生物科技有限公司 |
取代氮杂环衍生物及其应用
|
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
|
US10196384B2
(en)
|
2015-03-31 |
2019-02-05 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR modulators
|
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|